Version 1
: Received: 6 June 2024 / Approved: 7 June 2024 / Online: 7 June 2024 (07:52:28 CEST)
How to cite:
Pellon-Téllez, K.; Fernandez-Vargas, O. E.; Cornejo-Juárez, P.; Martin-Onraet, A.; Rubalcava-Lara, L. F.; Alvidrez-González, R. A.; Bonilla-Salcedo, A. Y.; Valero-Saldaña, L.; Acosta-Maldonado, B. L. Tuberculosis Reactivation in Hematopoietic Stem Cell Transplant Recipients: A Preemptive Strategy in an Endemic Country. Preprints2024, 2024060458. https://doi.org/10.20944/preprints202406.0458.v1
Pellon-Téllez, K.; Fernandez-Vargas, O. E.; Cornejo-Juárez, P.; Martin-Onraet, A.; Rubalcava-Lara, L. F.; Alvidrez-González, R. A.; Bonilla-Salcedo, A. Y.; Valero-Saldaña, L.; Acosta-Maldonado, B. L. Tuberculosis Reactivation in Hematopoietic Stem Cell Transplant Recipients: A Preemptive Strategy in an Endemic Country. Preprints 2024, 2024060458. https://doi.org/10.20944/preprints202406.0458.v1
Pellon-Téllez, K.; Fernandez-Vargas, O. E.; Cornejo-Juárez, P.; Martin-Onraet, A.; Rubalcava-Lara, L. F.; Alvidrez-González, R. A.; Bonilla-Salcedo, A. Y.; Valero-Saldaña, L.; Acosta-Maldonado, B. L. Tuberculosis Reactivation in Hematopoietic Stem Cell Transplant Recipients: A Preemptive Strategy in an Endemic Country. Preprints2024, 2024060458. https://doi.org/10.20944/preprints202406.0458.v1
APA Style
Pellon-Téllez, K., Fernandez-Vargas, O. E., Cornejo-Juárez, P., Martin-Onraet, A., Rubalcava-Lara, L. F., Alvidrez-González, R. A., Bonilla-Salcedo, A. Y., Valero-Saldaña, L., & Acosta-Maldonado, B. L. (2024). Tuberculosis Reactivation in Hematopoietic Stem Cell Transplant Recipients: A Preemptive Strategy in an Endemic Country. Preprints. https://doi.org/10.20944/preprints202406.0458.v1
Chicago/Turabian Style
Pellon-Téllez, K., Luis Valero-Saldaña and Brenda Lizeth Acosta-Maldonado. 2024 "Tuberculosis Reactivation in Hematopoietic Stem Cell Transplant Recipients: A Preemptive Strategy in an Endemic Country" Preprints. https://doi.org/10.20944/preprints202406.0458.v1
Abstract
Tuberculosis (TB) remains a global public health issue, particularly in developing countries. Hematopoietic stem cell transplant (HSCT) recipients are at elevated risk for TB due to immunosuppression. This retrospective study (2005-2022) assessed a preemptive latent tuberculosis infection (LTBI) screening and treatment strategy in 338 HSCT recipients and their donors. Screening included tuberculin skin test (TST) or QuantiFERON-TB Gold (QFT), and pulmonary imaging, with positive cases receiving isoniazid (INH) therapy. Statistical analyses aimed to compare TB reactivation rates, overall survival (OS), and relapse-free survival (RFS) across HSCT groups. Of 338 patients, 92 (27%) were diagnosed with LTBI. Screening involved TST in 325 cases and QFT in 13. INH therapy was completed by 81 patients, with 5 discontinuing due to hepatotoxicity. The cumulative incidence of active TB was 0.6%, and LTBI reactivation rate in patients who received INH was 1.2%. LTBI status did not affect OS or RFS. Our study exemplifies the effectiveness of LTBI protocols incorporating TST/QFT and CT-scan testing, followed by INH therapy, in reducing TB reactivation among HSCT recipients in a high-burden region.
Keywords
Tuberculosis; Hematopoietic stem cell transplant; Antimicrobial prophylaxis; Tuberculosis control
Subject
Medicine and Pharmacology, Transplantation
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.